Abstracts tagged "genomics and systemic lupus erythematosus (SLE)"

Abstract Number: 1894 • 2018 ACR/ARHP Annual Meeting
Baricitinib-Associated Changes in Type l Interferon Gene Signature during a 24-Week Phase-2 Clinical SLE Trial
Thomas Dörner¹, Yoshiya Tanaka², Michelle Petri³, Josef S. Smolen⁴, Ernst R. Dow⁵, Richard E. Higgs⁵, Robert J. Benschop⁵, Adam Abel⁵, Maria E. Silk⁵, Stephanie de Bono⁵ and Robert W. Hoffman⁵, ¹Charité Universitätsmedizin Berlin and Deutsches Rheuma-Forschungszentrum (DRFZ), Berlin, Germany, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ⁵Eli Lilly and Company, Indianapolis, IN
Background/Purpose: In the phase 2 study JAHH (NCT02708095), treatment with baricitinib (bari), an oral selective Janus kinase 1/2 inhibitor approved for the treatment of RA,…
Abstract Number: 2272 • 2012 ACR/ARHP Annual Meeting
Gene Expression Signatures in Monocytes From Primary Antiphospholipd Syndrome, Systemic Lupus Erythematosus and Lupus with Antiphospholipid Syndrome Identify Specific Pathways Involved in the Pathogenesis of Atherosclerosis and Cardiovascular Disease
Chary Lopez-Pedrera¹, Sebastiano Messineo², Carlos Perez-Sanchez¹, Patricia Ruiz-Limon¹, Mª Angeles Aguirre³, Rosario M. Carretero-Prieto⁴, Antonio Rodriguez-Ariza¹, Nuria Barbarroja⁴, Francisco Velasco¹, Munther A. Khamashta⁵, Eduardo Collantes-Estevez¹ and Mª Jose Cuadrado⁶, ¹IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ²Dipartimento di Scienze della Salute, Universitá Magna Graecia di Catanzaro, Dipartimento di Scienze della Salute, Universitá Magna Graecia di Catanzaro, Italy., Catanzaro, Italy, ³Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ⁴Rheumatology Unit, IMIBIC-Reina Sofia University Hospital, Cordoba, Spain, ⁵Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ⁶Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by immune-mediated inflammation in multiple organ systems. SLE, primary Antiphospholipid syndrome (APS) and secondary APS (SAPS) share several…
Abstract Number: 970 • 2012 ACR/ARHP Annual Meeting
Genetic Interactions Between SNP Variants in C3 Receptor Subunits in Patients with SLE
Jeffrey C. Edberg¹, Christine W. Duarte², Amit Patki², Elizabeth E. Brown MPH³, Kenneth M. Kaufman⁴, Jennifer A. Kelly⁵, Mary E. Comeau⁶, Marta E. Alarcon-Riquelme on behalf of BIOLUPUS and GENLES⁷, Sang-Cheol Bae⁸, Lindsey A. Criswell⁹, Barry I. Freedman¹⁰, Patrick M. Gaffney¹¹, Gary S. Gilkeson¹², Chaim O. Jacob¹³, Judith A. James⁵, Diane L. Kamen¹⁴, Kathy Moser Sivils⁵, Timothy B. Niewold¹⁵, Robert H. Scofield¹⁶, Betty P. Tsao¹⁷, Timothy J. Vyse¹⁸, John B. Harley¹⁹, Carl D. Langefeld²⁰, Hemant Tiwari² and Robert P. Kimberly²¹, ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴1Center for Autoimmune Genomics and Etiology and Rheumatology Division, Cincinnati Children’s Hospital Medical Center and the University of Cincinnati, Cincinnati, OH, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Wake Forest University Health Sciences, Winston-Salem, NC, ⁷Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK, ⁸Hanyang University Hospital for Rheumatic Disease, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, ⁹Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ¹⁰Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, ¹¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ¹³Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ¹⁴Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, ¹⁵Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ¹⁶Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ¹⁷Medicine/Rheumatology, UCLA School of Medicine, Los Angeles, CA, ¹⁸Medical & Molecular Genetics, King's College London, London, United Kingdom, ¹⁹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ²⁰Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ²¹Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Genome-wide and candidate gene studies have supported a role for genes involved in immune complex processing as being important contributors to development of SLE. …

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].